1 | Mr Ahmed Dawoud | University of Southampton | Genetic abnormalities in myeloid disorders and clonal haemopoiesis | Egypt | International Award for Research in Leukaemia |
2 | Ms Sarah TESSIER | Telethon Kids Institute | Targeting DYRK1A: a key player in Down syndrome Leukemogenesis | France | International Award for Research in Leukaemia |
3 | Dr Richard Burt | UCL Cancer Institute | Defining the Role of the Microenvironment in Treatment Resistance in Acute Lymphoblastic Leukaemia (ALL) | United Kingdom | International Award for Research in Leukaemia |
4 | Dr Mingjing Xu | Princess Margaret Cancer Centre | Evaluation of phosphatidylserine decarboxylase (PISD) as a therapeutic target in acute myeloid leukemia (AML) | Canada | International Award for Research in Leukaemia |
5 | Dr Catherine Sawai | INSERM U1218 ACTION Laboratory | A novel transgenic model of chronic myeloid leukemia to study leukemic stem cells, mechanisms of their persistence, and their impact on normal hematopoietic stem cell function | France | International Award for Research in Leukaemia |
6 | Mr David Cruz Hernandez | Weatherall Institute of Molecular Medicine | Human Model of Down Syndrome-AML: Identifying mechanisms of differentiation arrest leading to acute myeloid leukaemia | United Kingdom | International Award for Research in Leukaemia |
7 | Dr Wenjuan Liao | University of Colorado Denver | MLL2 as an Epigenetic Target in Acute Myelogenous Leukemia | United States | International Award for Research in Leukaemia |
8 | Dr Jose R Cortes | Institute for Cancer Genetics | The role of RHOA G17V in the pathogenesis of T-cell malignancies | United States | International Award for Research in Leukaemia |
9 | Dr Agatheeswaran Subramaniam | Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University | Inducing synthetic lethality as a novel therapeutic strategy to eradicate AML leukemic stem cells harboring STAG2 mutations | Sweden | International Award for Research in Leukaemia |